DNA damage response pathway is a promising therapeutic target for extrachromosomal DNA-positive tumours

Congcong Tian; Haiyun Gan

doi:10.1002/ctm2.70519

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (11) : e70519 DOI: 10.1002/ctm2.70519

INVITED LETTER

DNA damage response pathway is a promising therapeutic target for extrachromosomal DNA-positive tumours

Author information +

History +

PDF

Cite this article

Download citation ▾

Congcong Tian, Haiyun Gan. DNA damage response pathway is a promising therapeutic target for extrachromosomal DNA-positive tumours. Clinical and Translational Medicine, 2025, 15(11): e70519 DOI:10.1002/ctm2.70519

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Turner KM, Deshpande V, Beyter D, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017; 543: 122-125.

[2]	Bailey C, Pich O, Thol K, et al. Origins and impact of extrachromosomal DNA. Nature. 2024; 635: 193-200.

[3]	Weiser NE, Watkins TBK, Chang HY, Mischel PS. A guide to extrachromosomal DNA: cancer's dynamic circular genome. Cancer Discov. 2025; 15: 1105-1114.

[4]	Yang QL, Xie Y, Qiao K, Lim JYS, Wu S. Modern biology of extrachromosomal DNA: a decade-long voyage of discovery. Cell Res. 2025; 35: 11-22.

[5]	Hung KL, Jones MG, Wong IT, et al. Coordinated inheritance of extrachromosomal DNAs in cancer cells. Nature. 2024; 635: 201-209.

[6]	Chapman OS, Luebeck J, Sridhar S, et al. Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma. Nat Genet. 2023; 55: 2189-2199.

[7]	Morales C, García MJ, Ribas M, et al. Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol Cancer Ther. 2009; 8: 424-432.

[8]	Song K, Minami JK, Huang A, et al. Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges. Cancer Discov. 2022; 12: 1046-1069.

[9]	Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014; 343: 72-76.

[10]	Kang X, Li X, Zhou J, et al. Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. Cell. 2025; 188: 3405-3421.

[11]	Tang J, Weiser NE, Wang G, et al. Enhancing transcription-replication conflict targets ecDNA-positive cancers. Nature. 2024; 635: 210-218.

[12]	Li Q, Qian W, Zhang Y, et al. A new wave of innovations within the DNA damage response. Signal Transduct Target Ther. 2023; 8: 338.

[13]	Sadoughi F, Mirsafaei L, Dana PM, et al. The role of DNA damage response in chemo- and radio-resistance of cancer cells: can DDR inhibitors sole the problem?. DNA Repair. 2021; 101: 103074.

[14]	Uuskula-Reimand L, Wilson MD. Untangling the roles of TOP2A and TOP2B in transcription and cancer. Sci Adv. 2022; 8: eadd4920.

[15]	Thomas A, Pommier Y. Targeting Topoisomerase I in the era of precision medicine. Clin Cancer Res. 2019; 25: 6581-6589.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.